Announcements Trials
Browse Landscape

Status

No longer available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 7Expanded_access 2Observational 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 1CNS 1

Conditions

Glioma 1Gastrointestinal Stromal Tumors 1GIST 1

Interventions

tazemetostat 2regorafenib 2nirogacestat 2avapritinib 2Trabectedin 2selinexor 1ripretinib 1omburtamab I-131 1olaratumab 1mifamurtide 1glucarpidase 1ganitumab 1fludarabine phosphate 1balstilimab 1anlotinib 1Whole-Body Irradiation 1Tacrolimus 1TH 302 1Sunitinib 1Proton Pump Inhibitors 1Mycophenolic Acid 1Imatinib Mesylate 1Hydrocortisone 1FANG vaccine 1Everolimus 1DOXO-EMCH 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Carboxypeptidases 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × avapritinib × Sarcoma × Clear all
NCT04714086 2024-10-24

Expanded Access Program for Avapritinib

Blueprint Medicines Corporation

No longer available
CNSGastrointestinalSarcoma

Glioma, Gastrointestinal Stromal Tumors

NCT03862885 2020-07-27

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

Blueprint Medicines Corporation

Approved for marketing
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡